Diffuse Large B-Cell Lymphoma

Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL 3:02
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Shah • 15 Feb 2023
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy 5:36
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy
Veit Buecklein • 9 Dec 2022
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL 1:23
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL
Constantine Tam • 12 Dec 2022
Mechanisms of resistance to CAR T-cell therapies 5:09
Mechanisms of resistance to CAR T-cell therapies
John Rossi • 26 Aug 2021
CAR-T in DLBCL: 4-year follow-up data from ZUMA-1 2:13
CAR-T in DLBCL: 4-year follow-up data from ZUMA-1
Anna Sureda • 9 Feb 2021
The future of CAR T-cell therapy in lymphoma 2:15
The future of CAR T-cell therapy in lymphoma
Anna Sureda • 9 Feb 2021
Liso-cel for R/R large B-cell lymphoma 1:44
Liso-cel for R/R large B-cell lymphoma
Ulrich Jäger • 9 Feb 2021
Real-world efficacy & safety data: CAR-T in DLBCL 3:05
Real-world efficacy & safety data: CAR-T in DLBCL
Matthew Frigault • 1 Sep 2020
Challenges associated with CAR T-cell production 1:45
Challenges associated with CAR T-cell production
Valentín Ortiz-Maldonado • 1 Sep 2020
Selecting DLBCL patients for CAR T-cell therapies 4:28
Selecting DLBCL patients for CAR T-cell therapies
Anna Sureda • 1 Sep 2020
Tocilizumab: CAR T-cell therapy in DLBCL 2:18
Tocilizumab: CAR T-cell therapy in DLBCL
Matthew Frigault • 1 Sep 2020
The content of VJRegenMed is intended for healthcare professionals